首页> 外文OA文献 >Conventional and pretargeted radioimmunotherapy using bismuth-213 to target and treat non-Hodgkin lymphomas expressing CD20: a preclinical model toward optimal consolidation therapy to eradicate minimal residual disease

【2h】

Conventional and pretargeted radioimmunotherapy using bismuth-213 to target and treat non-Hodgkin lymphomas expressing CD20: a preclinical model toward optimal consolidation therapy to eradicate minimal residual disease

机译：使用铋213靶向和治疗表达CD20的非霍奇金淋巴瘤的常规放射疗法和预靶向放射免疫疗法：一种临床最佳治疗前模型，旨在消除最小残留疾病的最佳巩固疗法

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Park, Steven I.; Shenoi, Jaideep; Pagel, John M.; Hamlin, Don K.; Wilbur, D. Scott; Orgun, Nural; Kenoyer, Aimee L.; Frayo, Shani; Axtman, Amanda; Bäck, Tom; Lin, Yukang; Fisher, Darrell R.; Gopal, Ajay K.; Green, Damian J.; Press, Oliver W.;
展开▼
作者单位

展开▼
年度 2010
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
专利

1. Conventional and pretargeted radioimmunotherapy using bismuth-213 to target and treat non-Hodgkin lymphomas expressing CD20: a preclinical model toward optimal consolidation therapy to eradicate minimal residual disease. [J] . Park SI, Shenoi J, Pagel JM, Blood: The Journal of the American Society of Hematology . 2010,第20期

机译：使用铋213靶向和治疗表达CD20的非霍奇金淋巴瘤的常规放射疗法和预靶向放射免疫疗法：一种临床基础模型，旨在最佳合并治疗以根除最小的残留疾病。
2. Conventional and pretargeted radioimmunotherapy using bismuth-213 to target and treat non-Hodgkin lymphomas expressing CD20: a preclinical model toward optimal consolidation therapy to eradicate minimal residual disease. [J] . Park SI, Shenoi J, Pagel JM, Blood: The Journal of the American Society of Hematology . 2010,第20期

机译：使用铋213靶向和治疗表达CD20的非霍奇金淋巴瘤的常规放射疗法和预靶向放射免疫疗法：一种临床基础模型，旨在最佳合并治疗以根除最小的残留疾病。
3. Pretargeted Versus Directly Targeted Radioimmunotherapy Combined with Anti-CD20 Antibody Consolidation Therapy of Non-Hodgkin Lymphoma. [J] . Goldenberg DM The Journal of Nuclear Medicine . 2009,第3期

机译：预靶向与直接靶向放射免疫疗法相结合的非霍奇金淋巴瘤抗CD20抗体巩固疗法。
4. Modeling Radioimmunotherapy with Anti-CD20 Antibody - Optimal Preload Depending on Lymphoma Transcapillary Solute Exchange [C] . P. Kletting, S.N. Reske, G. Glatting World congress on medical physics and biomedical engineering;International congress of the IUPESM . 2011

机译：用抗CD20抗体模拟放射免疫疗法-最佳预载取决于淋巴瘤经毛细血管溶质交换
5. Studies of targeted therapies against human T lymphotropic virus type-1 adult T-cell lymphoma in preclinical animal models. [D] . Zimmerman, Bevin. 2009

机译：在临床前动物模型中针对人类T淋巴细胞病毒1型成人T细胞淋巴瘤的靶向疗法的研究。
6. Lymphoid Neoplasia: Conventional and pretargeted radioimmunotherapy using bismuth-213 to target and treat non-Hodgkin lymphomas expressing CD20: a preclinical model toward optimal consolidation therapy to eradicate minimal residual disease [O] . Steven I. Park, Jaideep Shenoi, John M. Pagel, -1

机译：淋巴瘤形成：使用铋213靶向和治疗表达CD20的非霍奇金淋巴瘤的常规放射疗法和预靶向放射免疫疗法：一种临床可行的临床模型旨在最佳合并治疗以根除最小残留病
7. Pretargeted Versus Directly Targeted Radioimmunotherapy Combined with Anti-CD20 Antibody Consolidation Therapy of Non-Hodgkin Lymphoma [O] . Robert M. Sharkey, Habibe Karacay, Christine R. Johnson, 2009

机译：预靶向与直接有针对性的放射免疫疗法相结合的非霍奇金淋巴瘤的抗CD20抗体固结疗法

Conventional and pretargeted radioimmunotherapy using bismuth-213 to target and treat non-Hodgkin lymphomas expressing CD20: a preclinical model toward optimal consolidation therapy to eradicate minimal residual disease

著录项

相似文献

相关主题

期刊订阅